Williamson Richard, Smaldone Marc C, Gibbons Erin P, Smith Ryan P, Beriwal Sushil, Benoit Ronald M
Department of Urology, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
Urology. 2009 Feb;73(2):369-73. doi: 10.1016/j.urology.2008.06.052. Epub 2008 Aug 15.
To determine the safety of prostate brachytherapy in patients with clinically localized prostate cancer who have undergone proctocolectomy with ileal pouch-anal anastomosis (IPAA).
We performed a retrospective chart review of patients with a prior history of IPAA reconstruction who underwent prostate brachytherapy at our institution. Clinical records were reviewed for demographic characteristics, postoperative dosimetry, changes in bowel function, and oncologic outcomes. Data were analyzed using descriptive statistics.
Five patients with an IPAA underwent prostate brachytherapy for clinically localized prostate cancer. Mean time from colorectal reconstruction to prostate brachytherapy was 6.3 years. Adequate dosimetry (mean D90 114.9%, mean V100 91.1%, mean R100 0.76 mL) was achieved in each patient. Bowel frequency worsened in the immediate postoperative period in all patients, but all patients returned to their baseline bowel pattern by 4 months after their procedure. Serious complications, such as J-pouch ulcers, fistulas, or fecal incontinence, did not occur in these patients.
Prostate brachytherapy is a safe treatment option in patients with clinically localized prostate cancer and a history of proctocolectomy and IPAA reconstruction.
确定在接受回肠储袋肛管吻合术(IPAA)直肠结肠切除术的临床局限性前列腺癌患者中,前列腺近距离放射治疗的安全性。
我们对在我院接受前列腺近距离放射治疗且有IPAA重建既往史的患者进行了回顾性病历审查。审查临床记录以了解人口统计学特征、术后剂量测定、肠道功能变化和肿瘤学结果。使用描述性统计分析数据。
5例接受IPAA的患者因临床局限性前列腺癌接受了前列腺近距离放射治疗。从结直肠重建到前列腺近距离放射治疗的平均时间为6.3年。每位患者均实现了足够的剂量测定(平均D90为114.9%,平均V100为91.1%,平均R100为0.76 mL)。所有患者术后近期肠道频率均恶化,但所有患者在术后4个月均恢复至基线排便模式。这些患者未发生严重并发症,如J型储袋溃疡、瘘管或大便失禁。
对于有临床局限性前列腺癌且有直肠结肠切除术和IPAA重建病史的患者,前列腺近距离放射治疗是一种安全的治疗选择。